Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment
Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment BROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ — Vensica Medical (“Vensica”), a pioneering urology therapeutics company, today announced the successful closing…